A specialized pro-resolving mediator
Technical Support & Resources

Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

PCTR1

Item No. 19064

Product Insert (PDF)Safety Data Sheet (SDS) (PDF)
Technical Information
Formal Name
(4Z,7Z,10Z,12E,14E,16R,17S,19Z)-16-(((R)-2-((S)-4-amino-4-carboxybutanamido)-3-((carboxymethyl)amino)-3-oxopropyl)thio)-17-hydroxydocosa-4,7,10,12,14,19-hexaenoic acid
CAS Number
1810710-59-8
Synonyms
  • Protein Conjugates in Tissue Regeneration 1
Molecular Formula
C32H47N3O9S
Formula Weight
649.8
Purity
≥96%
Formulation (Request formulation change)
A 100 µg/ml solution in ethanol
Solubility(Learn about Variance in Solubility)
DMF: 50 mg/mlDMSO: 50 mg/mlEthanol: 1 mg/mlEthanol/H20 (95:5): 2 mg/mlPBS (pH 7.2): 0.1 mg/ml
λmax
283, 293 nm
SMILES
CC/C=C\C[C@H](O)[C@H](SC[C@@H](C(NCC(O)=O)=O)NC(CC[C@@H](C(O)=O)N)=O)/C=C/C=C/C=C\C/C=C\C/C=C\CCC(O)=O
InChi Code
InChI=1S/C32H47N3O9S/c1-2-3-14-17-26(36)27(18-15-12-10-8-6-4-5-7-9-11-13-16-19-29(38)39)45-23-25(31(42)34-22-30(40)41)35-28(37)21-20-24(33)32(43)44/h3,5-8,10-15,18,24-27,36H,2,4,9,16-17,19-23,33H2,1H3,(H,34,42)(H,35,37)(H,38,39)(H,40,41)(H,43,44)/b7-
InChi Key
RYALZZFZNGJXAF-KMDXQAAMSA-N
Shipping & Storage Information
Storage
-80°C
Shipping
Dry ice in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Download most recent Certificate of Analysis for this product

    10 µg

    $203

    Add

    25 µg

    $481

    Add

    50 µg

    $861

    Add

    100 µg

    $1,518

    Add
    Lipid Resource Center
    Discover Products & Resources for Lipid Research
    • High-purity lipid standards
    • Lipid roles in biology
    • Lipids in health & disease
    • Lipids for pharmaceutical development
    • Protocols, advice, & resources
    EXPLORE NOW
    Product Description

    Protectin conjugates in tissue regeneration 1 (PCTR1) is a specialized pro-resolving mediator (SPM) synthesized from docosahexaenoic acid (DHA; Item No. 90310).1 DHA is oxidized to 16S,17S-epoxy-protectin, which is then converted to PCTR1 by glutathione S-transferase.1,2 PCTR1 levels increase during resolution of acute microbial-induced peritonitis in mice.3 PCTR1 (30 ng, i.p.) administration 12 hours post-infection increases macrophage numbers and activity and shortens the resolution phase of inflammation by 57%. It also reduces the levels of PGE2 (Item No. 14010), PGD2 (Item No. 12010), and TXB2 (Item No. 19030) in peritoneal exudates.

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Rodriguez, A.R., and Spur, B.W. Total synthesis of pro-resolving and tissue-regenerative protectin sulfido-conjugates. Tetrahedron Lett. 56(42), 5811-5815 (2015).

    2. Aursnes, M., Tungen, J.E., Colas, R.A., et al. Synthesis of the 16S,17S-epoxyprotectin intermediate in the biosynthesis of protectins by human macrophages. J. Nat. Prod. 8(12), 2924-2931 (2015).

    3. Ramon, S., Dalli, J., Sanger, J.M., et al. The protectin PCTR1 is produced by human M2 macrophages and enhances resolution of infectious inflammation. Am. J. Pathol. 186(4), 962-973 (2016).